About Mast Cell Tumors
Treatment & Prognosis of Mast Cell Tumors
Facts About Kinavet
Benefits of Kinavet
How to Use Kinavet
Important Safety Information
Where to Get Kinavet
What the Experts Say
Who We Are
Facts About Kinavet
Kinavet-CA1® belongs to the family of drugs called tyrosine kinase receptor inhibitors, which over the last decade have helped to revolutionize the management of certain human cancers and have now been successfully developed for veterinary medicine. This targeted therapy inhibits cellular signaling pathways that regulate key cell functions and survival.
The main cellular targets of Kinavet-CA1® are mast cells. Kinavet-CA1® has been designed specifically to target mast cells and is approved for the treatment of non-resectable canine mast cell tumors*. Kinavet-CA1® represents cutting-edge technology in the treatment of cancer through its ability to target those cells or signaling pathways responsible for tumor growth. By targeting mast cells it therefore works directly at the origin of the tumor.
Kinavet-CA1® is a targeted therapy. Kinavet-CA1® is optimized to target just a few key tyrosine kinases that are implicated in various diseases, while not inhibiting, at therapeutic doses, those tyrosine kinases attributed to possible toxicity. This permits Kinavet-CA1® to be administered at higher doses for a more potent therapeutic effect, while maintaining an acceptable level of tolerability and better safety profile compared to multi-targeting drugs or traditional chemotherapies (for example, cytotoxic drugs).
Kinavet-CA1® is not a chemotherapy drug. Several important distinctions exist including that unlike cytotoxic chemotherapies, which inhibit replication of a great many cells including healthy and useful ones, Kinavet-CA1® is a targeted therapy that limits collateral damage to healthy tissue.
Kinavet-CA1® is easy to use. Kinavet-CA1® is delivered orally in tablet form and can be administered everyday directly by the owner at their home.
Kinavet-CA1® is an effective treatment of mast cell tumors. Clinical trials of Kinavet-CA1® have scientifically proven it to be a valuable anti-cancer treatment with possible long term benefits. At least 50% of dogs treated with Kinavet-CA1® had their tumor half in size during the first 6 months.
Kinavet-CA1® is a safe treatment of mast cell tumors. Kinavet-CA1® is generally well tolerated with medically manageable side-effects.
Kinavet-CA1® was associated with life-threatening or fatal hypoalbuminemia an anemia in field studies and the 39-week safety study. The studies provide evidence that severe adverse reactions may be prevented if dogs are monitored for hypoalbumenemia every 2 weeks and for anemia every 4 weeks, and treatment is discontinued if hypoalbuminemia, protenuria or anemia occur.
Do NOT initiate Kinavet-CA1® tablet treatment in dogs with: hypoalbuminemia, proteinuria, azotemia, anemia, neutropenia or hyperbilirubinemia.
The safe use of Kinavet-CA1® tablets has not been evaluated in dogs younger than 2 years of ago and cannot be safely dosed in dogs weighing less than 7kg (15.4lbs).
For more details on potential side-effects of Kinavet-CA1® in canines, please refer to the package insert.
Kinavet-CA1® tablets are indicated for the treatment of nonresectable Grade II or III cutaneous mast cell tumors in dogs that have not previously received radiotherapy and/or chemotherapy except corticosteroids. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal Law to use this product other than as directed in the labeling.
